Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 15Other hematologic neoplasm 11Myeloid 1

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

fludarabine 32Specimen Handling 30Cyclophosphamide 28Azacitidine 28venetoclax 27Biopsy 24fludarabine phosphate 23ruxolitinib 18Whole-Body Irradiation 18Cytarabine 18Busulfan 18Mycophenolic Acid 17Tacrolimus 16asciminib 15Melphalan 14Injections 13Decitabine 13decitabine and cedazuridine drug combination 11X-Rays 11Stem Cell Transplantation 11Magnetic Resonance Spectroscopy 11Granulocyte Colony-Stimulating Factor 11Sirolimus 10Peripheral Blood Stem Cell Transplantation 10Cyclosporine 10Thiotepa 9Filgrastim 8nilotinib 7Methotrexate 7Imatinib Mesylate 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
azathiopurine × Myeloid × 90 days × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡